The US patent allowance, strong Phase 2 results, FDA Orphan Drug and Fast Track designations, and progress toward Phelan-McDermid syndrome trials position NEU favorably in the biotech space.
It’s a meaningful step toward commercializing NNZ-2591 for a rare, unmet medical need, with potential to drive positive market sentiment
Lets go NEU to $20. time to say goodbye to some of the shorters soon
Ann: US patent allowed for NNZ-2591 to treat Pitt Hopkins, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.78 |
Change
0.300(1.82%) |
Mkt cap ! $2.109B | |||
| Open | High | Low | Value | Volume |
| $16.65 | $16.90 | $16.33 | $3.692M | 220.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 213 | $16.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.78 | 167 | 3 |
View Market Depth
| Last trade - 14.20pm 29/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |